Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeGet StartedBook a Demo
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Reg FD DisclosureItem 7.01 · 8-KLOW RiskPositive

Lakewood-Amedex Biotherapeutics Inc.

Filed: Jul 15, 2026CIK: 0002079272
View on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Lakewood-Amedex Biotherapeutics announced the launch of Nu-3, a topically delivered antimicrobial gel for treating infected diabetic foot ulcers, supported by preclinical and clinical data and backed by the company's intellectual property portfolio in drug-resistant infection treatment.

Key Takeaways

Nu-3 is the company's lead program targeting infected diabetic foot ulcers, a significant unmet medical need with serious patient risks

The product launch is supported by extensive preclinical and clinical data demonstrating efficacy

2 more takeaways

Filing Overview

Form Type8-K
Filing DateJul 15, 2026
Item7.01
CategoryReg FD Disclosure
CIK0002079272
Accession #0002079272
Risk LevelLOW
SentimentPositive
Signalopportunity
Topics
product launchregulatory

What This Means

The company is making a public disclosure under Regulation FD, often sharing material information to ensure equal access.
View Full Filing on SEC.govBrowse More Filings